Outlook Therapeutics, Inc. announced it raised $4.01 Million in an initial filing from an offering of $4.01 Million
Outlook Therapeutics, Inc. announced it raised $4.01 Million in an initial filing from an offering of $4.01 Million
02/12/21, 1:04 PM
Location
iselinMoney raised
$4.01 million
Industry
biotechnology
Round Type
seed
Company Info
Location
485 route 1 south
iselin, new jersey, united states
Additional Info
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.